RE:RE:RE:Loving EMH at these prices. 5$ + again soon! 💎💎I beg to differ
. $46 MM Cash Available from VFF Sale
. No long term debt
. Current Market Value 206 Million Shares O/S x 0.37 cents = $76.22 Million ..That's crazy cheap.. If you subtract the $46 MM Cash, your left with about a $30 Million Market Value.
Distinctly Positioned Operating Assets
1-RICHMOND BC ORGANIC
HEALTH & WELLNESS
• Premium organic flower
PURPOSE-BUILT ORGANIC-CERTIFIED OPERATION
• First greenhouse: full production 78K sq ft Capacity 3400 KG
• Second greenhouse: Substantially completed 78sq ft Capacity Near Completion
2-VERDLITE, QC
PREMIUM CRAFT
• Recreational & wellness
• Quebec identity
INDOOR CANNABIS PRODUCTION FACILITY 88K sq ft Capacity 5000 KG
• Packaging, processing and pre-roll capacity
• Craft strains
3-COMMERCE CIRCLE, BC
HEALTH & WELLNESS
• High-quality medicinal flower and extract
MEDICAL CANNABIS HUB 10K sq ft.
• Research, processing & storage
• Next generation product development
• Small-batch extraction
Highlights of Emerald Accomplishments & Growth Plans
Marketing & Sales
The Company’s “Emerald” branded dried flower products and SYNC™ oil products are currently being sold across Canada. The Emerald brand conveys quality consumer cannabis experiences while the SYNC™ brand provides approachable products in non-inhalable formats. Additionally, the Company successfully launched its Quebec-exclusive Souvenir™ brand for which all manufacturing from seed to sale takes place in Quebec. All three brands are poised for growth in 2021 with new formats for consumption, new strain offerings and new product lines all in development. The Company is currently also developing a new brand to complement its existing lines and bring additional consumer benefits to the Canadian cannabis market.
Emerald currently has 12 product SKUs across 4 distinct product lines and 3 brands. By year-end the Company expects to have 26 product SKUs across 11 distinct product lines and 5 brands. Multiple new product categories and SKUs along with 2 new brands are expected to be launched by mid-year. This significant expansion of product choices is intended to meet unique needs and tastes in the Canadian marketplace.
In May 2019, Emerald launched its first SYNC™ oil, the SYNC™ 25 CBD product. Since then, we have expanded the SYNC™ product line to six products, most recently launching SYNC™ 100 CBD, the highest potency CBD product on the recreational market, and SYNC™ 30 THC Mango + Myrcene, the market’s first flavoured THC oil. Based on natural ingredients, SYNC™ provides controlled dosing products in a variety of flavours and potencies for our consumers' needs.
Our marketing & sales team is currently being expanded in a targeted manner to leverage its prior success and strong market knowledge. This expansion adds depth to Emerald’s sales strategy of exposing products to retail channels and educating budtenders about the distinct attributes of Emerald’s dried flower and specialty product offerings. This group will spearhead and launch new products and brands based on consumer needs and tastes that are intended to drive tangible revenue growth through 2021 starting in the second quarter.
Product Lines & Product Development
Emerald’s new product development (NPD) team is also being expanded, with significant resources being allocated to expand its product creation and development efforts.
The team will bring new Emerald product categories to fruition and create product line extensions, offering new SKUs within those product families through a combination of internal expertise and development effort as well as through collaborations to leverage the capabilities of third-party vendors.
Technologies and products may originate internally or externally. The team also has a mandate to create new intellectual property involving patents or trade secrets and is empowered to consider new concepts based on a spectrum of possibilities including formulations, physical delivery, bioavailability, and therapeutic capabilities, and where it fulfills the brand promise, incorporate the attributes of “predictable action” and “Defined Dose™” to give consumers the benefit of discreet, convenient consumption and reproducible outcomes in terms of rapid onset and offset of effects.
Emerald continues to grow select cannabis strains in its facilities and is also planning to introduce a specialty craft cannabis product line. These facilities are also complemented by a specialty processing and medical cannabis facility in Victoria, BC.
The NPD group is working in a special-purpose facility in BC that was explicitly designed and licensed for the development of novel cannabinoid-based specialty products.
Strategic Opportunities
As Emerald structures its planned new Beryllium (Be4 ) business division, the company is focusing on targeted opportunities to build strategic partnerships as well as in-license, acquire or invest in products, technologies, or companies. It already has access to deal flow and clinical development options representing a myriad of new opportunities both within and outside of Canada. Beryllium will pursue opportunities that provide patients with differentiated new offerings and solutions to fulfill unmet needs.